文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹自身免疫性与大疱性皮肤病

外用糖皮质激素处方的人群队列研究

Use of topical glucocorticoids: a population-based cohort study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-02-24

基于法国EGB数据库(覆盖约90%人群的1/97随机样本),2011—2015年共662 531人记录,其中220 345人(33.3%)至少一次被处方外用糖皮质激素。年处方患病率从2011年11.7%升至2015年12.5%,共配发922 026支,主要为高效价药物,73.1%由全科医生处方。

要点

  • 约12%的法国普通人群每年至少被处方一次外用糖皮质激素。
  • 处方主要由全科医生开具,皮肤科医生占比不足四分之一。
  • 每年至少24支的高用量患者以男性、年长者更多,且药物效价更强。

核心结论

  • 约12%的法国普通人群每年至少被处方一次外用糖皮质激素,处方主要来自全科医生。

研究设计与样本

  • 基于法国EGB数据库(主医保系统覆盖人群的1/97随机抽样,约占总人口90%)的5年人群队列研究,纳入2011年1月1日至2015年12月31日所有被处方外用糖皮质激素的患者。

主要发现

  • 5年研究期内EGB记录662 531人,其中220 345人(33.3%)至少一次被处方外用糖皮质激素。
  • 外用糖皮质激素处方患病率从2011年11.7%规律上升至2015年12.5%。
  • 共配发922 026支外用糖皮质激素,主要为高效价药物,73.1%由全科医生处方。
  • 1713例(0.8%)患者在一个日历年内被处方至少24支,该组男性更多(P < 0.001)且年龄更大(P < 0.001)。
  • 高用量患者获配的124 844支药物效价强于总体处方人群(P < 0.001),68.1%由全科医生处方。

临床怎么用

  • 法国经验提示外用糖皮质激素处方广泛,全科医生是主要处方者,皮肤科医生占比不足四分之一。
  • 对每年使用至少24支的高用量患者,需关注男性、年长者及高效价药物使用情况。

局限性

  • 仅371例(21.7%)患者有处方原因记录,主要涉及银屑病、自身免疫性大疱性皮肤病和湿疹。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the prescriptions of topical glucocorticoids in the general population. OBJECTIVES: To report an overall picture of topical glucocorticoid prescriptions in France. METHODS: This study used the Echantillon Généraliste de Bénéficiaires (EGB) database, a 1/97th random sampling of the French population covered by the main national healthcare insurance system (approximately 90% of the whole population). All patients prescribed topical glucocorticoids over a 5-year period (1 January 2011 to 31 December 2015) were identified using a specific code list for topical glucocorticoids. RESULTS: Over the 5-year study period, 662 531 individuals were recorded for at least 1 day in the EGB. Among them, 220 345 (33.3%) were prescribed at least once topical glucocorticoid. The prevalence of topical glucocorticoid prescription increased regularly from 2011 (11.7%) to 2015 (12.5%). A total of 922 026 tubes of topical glucocorticoids were dispensed, mainly high-potency glucocorticoids, and were mainly prescribed by general practitioners (73.1%). A total of 1713 (0.8%) patients were prescribed at least 24 tubes over a calendar year. These patients were more frequently men (P < 0.001) and older (P < 0.001) than the overall population of patients prescribed topical glucocorticoids. The 124 844 tubes prescribed to these patients had stronger potency than those prescribed to the overall population (P < 0.001) and were mostly prescribed by general practitioners (68.1%). The reasons for prescription were available for only 371 patients (21.7%) and were mainly psoriasis, auto-immune bullous dermatoses and eczema. CONCLUSION: About 12% of the French general population is prescribed topical glucocorticoids at least once each year. Most prescriptions are issued by general practitioners, dermatologists being the prescribers in less than one-quarter of cases.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. El-Khoury M, Thay R, N'Diaye M, et al. Use of topical glucocorticoids: a population-based cohort study. J Eur Acad Dermatol Venereol. 2017. PMID: 28150352. doi:10.1111/jdv.14149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。